ID   HG-3
AC   CVCL_Y547
SY   HG3
DR   ArrayExpress; E-MTAB-4527
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   Cell_Model_Passport; SIDM01817
DR   DepMap; ACH-001520
DR   DSMZ; ACC-765
DR   DSMZCellDive; ACC-765
DR   Wikidata; Q54883310
RX   PubMed=22720208;
RX   PubMed=23297799;
RX   PubMed=27566572;
RX   PubMed=28489572;
RX   PubMed=31160637;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572).
CC   Doubling time: ~50-70 hours (DSMZ=ACC-765).
CC   HLA typing: A*11:01:01,31:01:02; B*07:02:01,15:01:01; C*03:03:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-765).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DepMap=ACH-001520; DSMZ=ACC-765
ST   Amelogenin: X,Y
ST   CSF1PO: 11,14
ST   D13S317: 11,13
ST   D16S539: 9,12
ST   D18S51: 14,16
ST   D19S433: 15,16
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 17,18
ST   D5S818: 11
ST   D7S820: 8,13
ST   D8S1179: 11,15
ST   FGA: 23,24
ST   Penta D: 9,10
ST   Penta E: 11,12
ST   TH01: 7,9.3
ST   TPOX: 8,12
ST   vWA: 17,20
DI   NCIt; C3163; Chronic lymphocytic leukemia
DI   ORDO; Orphanet_67038; B-cell chronic lymphocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Transformed cell line
DT   Created: 07-11-14; Last updated: 02-05-24; Version: 15
//
RX   PubMed=22720208; DOI=10.4161/onci.1.1.18400;
RA   Rosen A., Bergh A.-C., Gogolak P., Evaldsson C., Myhrinder A.L.,
RA   Hellqvist E., Rasul A., Bjorkholm M., Jansson M., Mansouri L.,
RA   Liu A.-Q., Teh B.T., Rosenquist R., Klein E.;
RT   "Lymphoblastoid cell line with B1 cell characteristics established
RT   from a chronic lymphocytic leukemia clone by in vitro EBV infection.";
RL   OncoImmunology 1:18-27(2012).
//
RX   PubMed=23297799; DOI=10.3109/10428194.2013.764418;
RA   Myhrinder A.L., Hellqvist E., Bergh A.-C., Jansson M.,
RA   Nilsson K., Hultman P., Jonasson J., Buhl A.M., Pedersen L.B.,
RA   Jurlander J., Klein E., Weit N., Herling M., Rosenquist R., Rosen A.;
RT   "Molecular characterization of neoplastic and normal 'sister'
RT   lymphoblastoid B-cell lines from chronic lymphocytic leukemia.";
RL   Leuk. Lymphoma 54:1769-1779(2013).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=28489572; DOI=10.18632/oncotarget.17246;
RA   Russo M., Milito A., Spagnuolo C., Carbone V., Rosen A., Minasi P.,
RA   Lauria F., Russo G.L.;
RT   "CK2 and PI3K are direct molecular targets of quercetin in chronic
RT   lymphocytic leukaemia.";
RL   Oncotarget 8:42571-42587(2017).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//